Oppenheimer upgraded shares of The Medicines (NASDAQ:MDCO) from a market perform rating to a buy rating in a research report report published on Wednesday. The firm currently has $50.00 price target on the stock. Oppenheimer also issued estimates for The Medicines’ FY2021 earnings at $0.83 EPS.
Several other equities research analysts have also recently weighed in on MDCO. Cowen reiterated a buy rating and issued a $54.00 price objective (down previously from $61.00) on shares of The Medicines in a report on Thursday, August 10th. TheStreet cut The Medicines from a c- rating to a d rating in a report on Wednesday, August 9th. Jefferies Group reiterated a buy rating and issued a $54.00 price objective (down previously from $62.00) on shares of The Medicines in a report on Thursday, August 10th. Citigroup upgraded The Medicines from a sell rating to an outperform rating in a report on Thursday. Finally, Zacks Investment Research upgraded The Medicines from a hold rating to a buy rating and set a $41.00 price objective for the company in a report on Tuesday, August 8th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the company. The stock currently has a consensus rating of Buy and an average target price of $53.67.
Shares of The Medicines (NASDAQ MDCO) opened at $28.50 on Wednesday. The Medicines has a fifty-two week low of $27.77 and a fifty-two week high of $55.95. The company has a quick ratio of 1.79, a current ratio of 2.31 and a debt-to-equity ratio of 3.42.
In other news, Director Alexander J. Denner bought 170,000 shares of the firm’s stock in a transaction dated Wednesday, November 29th. The stock was purchased at an average price of $30.03 per share, with a total value of $5,105,100.00. Following the transaction, the director now owns 6,663 shares of the company’s stock, valued at $200,089.89. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 8.22% of the stock is currently owned by corporate insiders.
Large investors have recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of The Medicines by 10.6% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,753 shares of the company’s stock worth $105,000 after acquiring an additional 264 shares in the last quarter. Quantbot Technologies LP bought a new position in shares of The Medicines in the 3rd quarter worth approximately $171,000. First Mercantile Trust Co. raised its position in shares of The Medicines by 2.5% in the 2nd quarter. First Mercantile Trust Co. now owns 4,767 shares of the company’s stock worth $181,000 after acquiring an additional 114 shares in the last quarter. SG Americas Securities LLC bought a new position in The Medicines during the 3rd quarter valued at approximately $198,000. Finally, Bluefin Trading LLC bought a new position in The Medicines during the 2nd quarter valued at approximately $214,000.
The Medicines Company Profile
The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin).
What are top analysts saying about The Medicines Company? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for The Medicines Company and related companies.